Hexapeptide-9

What is Hexapeptide-9?

Hexapeptide-9 is a synthetic six-residue peptide with the sequence Gly-Pro-Gln-Gly-Pro-Gln — two tandem repeats of the Gly-Pro-Gln triplet. Supplier documentation identifies that motif as occurring in collagen IV and collagen XVII, and the ingredient is marketed as a matrikine: a short fragment of a matrix protein that acts as a signal to the cells that build matrix, rather than as a building block itself. It reaches formulators under the trade name Collaxyl, developed by Vincience and now part of Ashland's personal-care portfolio. The commercial material is a dilute solution — the Collaxyl IS presentation is listed as water, butylene glycol and hexapeptide-9 — which is the source of a persistent confusion about use levels. Supplier guidance for the diluted complex is quoted in the range of roughly 0.5 to 3% of a finished formula, while the active peptide itself lands around 0.002 to 0.01%. Those are not conflicting figures; they are the same thing counted differently. The 0.002% figure is corroborated by the one randomised trial, which tested a serum at exactly that concentration. The choice of parent proteins is more interesting than most cosmetic-peptide origin stories. Collagen IV is the principal structural collagen of the basement membrane, and collagen XVII — also known as BP180, the autoantigen in bullous pemphigoid — is a transmembrane collagen at the dermal-epidermal junction that has become one of the genuine hotspots of skin-aging research, since epidermal stem cell maintenance depends on it. A peptide borrowed from the junction rather than from the dermis is at least pointed at a biologically defensible target. What that does not establish is function. Sharing a sequence with a protein is not the same as reproducing what the protein does, and the independent evidence that hexapeptide-9 engages basement-membrane biology at cosmetic concentrations is thin.

What Hexapeptide-9 Is Investigated For

Hexapeptide-9 is unusual among minor cosmetic peptides in having a properly designed randomised trial, and unusual in how carefully that trial needs to be read. Chang and colleagues (J Cosmet Dermatol 2025) randomised volunteers with aging skin to twice-daily 0.002% cyclized hexapeptide-9 serum, 0.002% retinol serum, or vehicle for 56 days. The peptide significantly reduced the number, area and roughness of both crow's feet and forehead wrinkles; retinol reduced only the area of crow's feet and the number and area of forehead wrinkles; and the peptide beat retinol on every measured outcome except crow's-feet roughness, with effects that grew with longer use. Two caveats change what that result means. First, the molecule tested was a cyclized derivative engineered for stability and permeability, not the linear hexapeptide-9 that appears on most ingredient lists — the authors are explicit that the innovation was the cyclization. Second, the retinol comparator was dosed at 0.002%, which is roughly 20 parts per million; over-the-counter retinol products typically sit between 0.1% and 1%, that is 50 to 500 times higher. Beating retinol at 0.002% is not evidence of beating retinol as consumers encounter it, and the paper does not claim otherwise. The honest reading is that a stabilised hexapeptide-9 derivative produced measurable wrinkle improvement against a vehicle control in a well-designed trial — which is already more than most cosmetic peptides can show. The second substantive piece of evidence points at the same problem from the other direction. A 2025 Materials Today Bio study paired hexapeptide-9 with a GABA-and-lactic-acid ionic liquid as a transdermal enhancer and measured 4.79-fold higher cumulative permeation and 7.89-fold higher subcutaneous retention at 12 hours versus no enhancer, together with PPAR pathway activation and reduced UV-induced oxidative stress, inflammation and matrix degradation. A five- to eightfold improvement from an enhancer is a direct statement about how poorly the peptide gets in on its own.

History & Discovery

Hexapeptide-9 entered the cosmetic market through Vincience, the French active-ingredient house that became part of International Specialty Products and then of Ashland, under the trade name Collaxyl. Its original commercial positioning was closer to wound repair and tissue cohesion than to wrinkles — the pitch concerned supporting the integrity of the dermal-epidermal junction — and the anti-wrinkle framing came later, as the broader cosmetic-peptide category consolidated around that claim. The design logic belongs to the matrikine wave of the late 1990s and 2000s, which produced Matrixyl, Matrixyl 3000 and the palmitoylated collagen fragments. Where most of those borrowed from interstitial collagen I, hexapeptide-9 took its Gly-Pro-Gln repeat from collagen IV and collagen XVII, aiming at the basement membrane instead of the dermis. At the time that was a differentiating choice more than a well-supported one; the biology that makes it look prescient arrived afterwards, as collagen XVII became a major focus in epidermal stem cell research through the 2016 Science paper on COL17A1 proteolysis in hair follicle aging and the 2019 Nature work on stem cell competition. For most of its commercial life the ingredient sat where most minor cosmetic peptides sit: supplier claims, in vitro data, no independent trial. That changed in July 2025 with the publication of a randomised, double-blinded, active- and vehicle-controlled trial in the Journal of Cosmetic Dermatology testing a cyclized hexapeptide-9 against retinol and vehicle — a genuinely better-designed study than most of the category has, carrying the caveat that it tested a modified derivative and a very low-dose retinol comparator. Earlier that same year, a Materials Today Bio paper paired the peptide with an ionic-liquid penetration enhancer and quantified how much its delivery could be improved, which is the other half of the picture.

How It Works

Skin is held together at the boundary between its top layer and the layer beneath by a thin sheet of specialised collagens. Hexapeptide-9 copies a short repeating sequence from two of those collagens. The idea is that when skin cells encounter that fragment, they read it the way they would read matrix breakdown — as a signal to rebuild — and step up production of the proteins that keep the boundary intact. The difficulty is getting a water-loving peptide past a barrier built to keep water-loving things out.

The matrikine concept underlying hexapeptide-9 is well established in principle: fragments released when extracellular matrix is degraded act as signals to fibroblasts and keratinocytes, which respond by upregulating matrix synthesis. Synthetic matrikines exploit that pathway by presenting the fragment without the preceding damage. Palmitoyl pentapeptide-4 and palmitoyl tripeptide-1 are the best-known examples, both drawn from interstitial collagen I. Hexapeptide-9's Gly-Pro-Gln-Gly-Pro-Gln sequence is attributed instead to collagen IV and collagen XVII, which places it at the dermal-epidermal junction rather than in the dermal matrix. That is a biologically meaningful distinction. Collagen IV forms the structural network of the basement membrane; type IV collagen content and basement-membrane organisation change measurably with age, and proteomic work on intrinsic aging has documented altered protein composition at the dermal-epidermal junction. Collagen XVII, the transmembrane collagen also known as BP180, anchors basal keratinocytes through hemidesmosomes and has emerged as a central node in epidermal stem cell biology: COL17A1 proteolysis drives transepidermal elimination of hair follicle stem cells, and stem cell competition for the basal niche is governed by its expression level. Reviews now explicitly frame collagen XVII as a stem cell niche target in skin aging and wound repair. Supplier material describes the peptide as acting as a matrikine in both collagens with the intention of supporting cohesion at that junction, and the one mechanistic study with independent publication points elsewhere: the 2025 ionic-liquid work attributed hexapeptide-9's protective effect against UV-induced damage mainly to activation of PPAR signalling, with downstream reductions in oxidative stress, inflammation, epidermal hyperplasia and collagen and elastic fibre degradation. PPAR activation is a plausible route to those outcomes but is not the matrikine mechanism the marketing describes, and the two have not been reconciled. Delivery remains the binding constraint. At roughly 600 daltons and highly hydrophilic, with no lipid conjugation, the peptide sits right at the practical limit for passive stratum corneum penetration. The measured 4.79-fold permeation and 7.89-fold retention gains from an ionic-liquid enhancer quantify how much room there is below that limit, and the cyclization strategy in the randomised trial was adopted for the same reason — the authors cite low stability and poor skin permeability as the problems they set out to solve.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Hexapeptide-9:

• 01The linear versus cyclized question. Every controlled efficacy claim for this ingredient comes from a trial of a cyclized derivative, while the ingredient on most product labels is the linear peptide. No study has compared the two, which means the main commercial form has no controlled human evidence at all.
• 02A fair retinoid comparison. The 0.002% retinol comparator in the randomised trial is 50 to 500 times below typical over-the-counter retinol concentrations. A comparison against 0.3% or 0.5% retinol would answer the question consumers are actually asking, and has not been run.
• 03Mechanism reconciliation. The ingredient is sold as a collagen IV and XVII matrikine, but the one independent mechanistic study attributes its effects mainly to PPAR signalling. No work demonstrates that hexapeptide-9 modulates collagen IV or collagen XVII expression at cosmetic concentrations, which leaves the marketed mechanism unverified.
• 04Where the effect plateaus. The randomised trial reported effects still growing at 56 days, so the duration needed to reach maximum benefit is unknown — unusual among cosmetic peptides, where the 8-to-16-week plateau is the convention.
• 05Independent replication. One randomised trial and one mechanistic paper constitute the entire independent literature. No second group has reproduced the clinical result, and supplier-associated data cannot substitute.
• 06Formal safety assessment. No CIR report or SCCS opinion exists for hexapeptide-9; the available evaluation is a bioinformatic hazard screen of a caffeoyl derivative. Long-term human exposure data stop at 56 days.
• 07Delivery in real products. Permeation gains of 4.79-fold and 7.89-fold with a specific ionic-liquid enhancer are impressive and almost certainly not representative of retail formulations. How much peptide commercial serums actually deliver to viable epidermis has not been measured, although analytical methods for quantifying cosmetic peptides in skin homogenates are now being developed.
• 08Ingredient traceability. Conflicting CAS registry assignments across suppliers make it harder than it should be to confirm that material sold as hexapeptide-9 is the same molecule the published work studied.

Forms & Administration

Topical only, in serums, essences and creams. Supplied to formulators as a dilute trade solution — the Collaxyl IS presentation lists water, butylene glycol and hexapeptide-9 — typically incorporated at roughly 0.5 to 3% of the finished product by weight of that diluted material, corresponding to approximately 0.002 to 0.01% of the peptide itself. The randomised trial used a 0.002% serum applied twice daily. Formulations pairing it with a penetration enhancer have measurably better delivery, and the cyclized derivative used in the trial was engineered for stability and permeability rather than being the standard commercial form; a product using it would normally say so. Compatible with the usual cosmetic base — humectants, niacinamide, ceramides, other peptides. No oral, injectable or compounded form exists or has any rationale.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Hexapeptide-9 is a cosmetic ingredient, not a drug. It is not approved to treat or prevent any medical condition, and no formal safety assessment specific to the ingredient has been published by the Cosmetic Ingredient Review or the SCCS.

Timeline of Effects

Common Questions

Who Hexapeptide-9 Is NOT For

Drug & Supplement Interactions

No pharmacological drug interactions are documented or expected. Systemic absorption from topical application of a hydrophilic hexapeptide at roughly 20 to 100 parts per million is negligible, plasma levels are not reached in any meaningful sense, and there is no mechanism by which it would interact with oral or injected medications. The relevant interaction space is entirely topical and formulation-level. Compatibility is broad. Hexapeptide-9 layers without difficulty alongside hyaluronic acid, glycerin, niacinamide, ceramides and other peptides including the palmitoylated matrikines and the neuropeptide-signalling inhibitors. High-concentration L-ascorbic acid is the main chemical caution: its low pH can destabilise peptide actives in the same layer, so vitamin C is conventionally used at a different time of day. Strong alpha-hydroxy and beta-hydroxy acid exfoliation applied simultaneously may degrade surface peptide and compound irritation, so spacing is sensible. Retinoids deserve a specific note because of how this ingredient is marketed. The randomised trial positioned cyclized hexapeptide-9 as an alternative to retinol — specifically for people for whom retinol's tolerability is the obstacle — rather than as something to layer with it. Using both is pharmacologically unremarkable and no antagonism is described, but no study has evaluated the combination for either additive benefit or additive irritation, so the honest answer is that it is untested rather than established as complementary. Patients using prescription topical dermatologic therapies — tretinoin, tazarotene, hydroquinone, topical antibiotics — should coordinate routines with their dermatologist, primarily for irritation management rather than for any true interaction.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions